Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.38
ACBFF's Cash-to-Debt is ranked higher than
65% of the 886 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.53 vs. ACBFF: 1.38 )
Ranked among companies with meaningful Cash-to-Debt only.
ACBFF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: No Debt Max: No Debt
Current: 1.38
0.02
No Debt
Equity-to-Asset 0.82
ACBFF's Equity-to-Asset is ranked higher than
68% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. ACBFF: 0.82 )
Ranked among companies with meaningful Equity-to-Asset only.
ACBFF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.32  Med: 0.74 Max: 1
Current: 0.82
0.32
1
Debt-to-Equity 0.15
ACBFF's Debt-to-Equity is ranked lower than
99.99% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. ACBFF: 0.15 )
Ranked among companies with meaningful Debt-to-Equity only.
ACBFF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.4 Max: 3.03
Current: 0.15
0
3.03
Debt-to-EBITDA -18.75
ACBFF's Debt-to-EBITDA is ranked higher than
96% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. ACBFF: -18.75 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ACBFF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -18.75  Med: -1.63 Max: -0.91
Current: -18.75
-18.75
-0.91
Piotroski F-Score: 2
Altman Z-Score: 10.48
Beneish M-Score: 1.32
WACC vs ROIC
3.11%
-10.86%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -88.76
ACBFF's Operating Margin % is ranked lower than
85% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.96 vs. ACBFF: -88.76 )
Ranked among companies with meaningful Operating Margin % only.
ACBFF' s Operating Margin % Range Over the Past 10 Years
Min: -340.38  Med: -318.97 Max: -53.36
Current: -88.76
-340.38
-53.36
Net Margin % -30.37
ACBFF's Net Margin % is ranked higher than
87% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. ACBFF: -30.37 )
Ranked among companies with meaningful Net Margin % only.
ACBFF' s Net Margin % Range Over the Past 10 Years
Min: -397.71  Med: -340.38 Max: -30.37
Current: -30.37
-397.71
-30.37
ROE % -2.50
ACBFF's ROE % is ranked lower than
61% of the 857 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.75 vs. ACBFF: -2.50 )
Ranked among companies with meaningful ROE % only.
ACBFF' s ROE % Range Over the Past 10 Years
Min: -339.81  Med: -22.02 Max: -2.5
Current: -2.5
-339.81
-2.5
ROA % -1.95
ACBFF's ROA % is ranked lower than
57% of the 888 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.29 vs. ACBFF: -1.95 )
Ranked among companies with meaningful ROA % only.
ACBFF' s ROA % Range Over the Past 10 Years
Min: -100.09  Med: -21.61 Max: -1.95
Current: -1.95
-100.09
-1.95
ROC (Joel Greenblatt) % -13.93
ACBFF's ROC (Joel Greenblatt) % is ranked lower than
59% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.64 vs. ACBFF: -13.93 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ACBFF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -33100  Med: -459.56 Max: -13.93
Current: -13.93
-33100
-13.93
3-Year EBITDA Growth Rate 22.30
ACBFF's 3-Year EBITDA Growth Rate is ranked higher than
71% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.90 vs. ACBFF: 22.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ACBFF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -102.7  Med: -30.75 Max: 22.3
Current: 22.3
-102.7
22.3
3-Year EPS without NRI Growth Rate 23.10
ACBFF's 3-Year EPS without NRI Growth Rate is ranked higher than
71% of the 657 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.20 vs. ACBFF: 23.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ACBFF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -26 Max: 23.1
Current: 23.1
0
23.1
GuruFocus has detected 5 Warning Signs with Aurora Cannabis Inc ACBFF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ACBFF's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with OTCPK:ACBFF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325411    SIC: 3741
Compare:TSE:4527, SHSE:600079, SHSE:600511, SHSE:600062, NSE:ALKEM, HKSE:02005, SZSE:000623, NAS:IRWD, BUD:RICHTER, SHSE:600380, TSE:4540, SZSE:002390, SHSE:603707, SZSE:000999, XTER:EVT, NYSE:TARO, NAS:SUPN, BOM:532296, TSE:4521, SZSE:300199 » details
Traded in other countries:ACB.Canada, 21P.Germany,
Headquarter Location:Canada
Aurora Cannabis Inc is a medical marijuana company. The Company is engaged in producing and distributing medical marijuana pursuant to the Marijuana for Medical Purposes Regulations.

Aurora Cannabis Inc is involved in the business of production and distribution of Marijuana. The firm's product portfolio includes Cannabis oil. Dried cannabis and Milled blend. It has categorized its products in Indica, Sativa and Hybrid types. The company has Production and sale of medical cannabis operating segment. It generates all of its revenues in Canada.

Ratios

vs
industry
vs
history
Forward PE Ratio 243.90
ACBFF's Forward PE Ratio is ranked lower than
94% of the 111 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.00 vs. ACBFF: 243.90 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 3.46
ACBFF's PB Ratio is ranked lower than
83% of the 843 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. ACBFF: 3.46 )
Ranked among companies with meaningful PB Ratio only.
ACBFF' s PB Ratio Range Over the Past 10 Years
Min: 0.26  Med: 0.96 Max: 19.18
Current: 3.46
0.26
19.18
PS Ratio 84.51
ACBFF's PS Ratio is ranked lower than
96% of the 784 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.25 vs. ACBFF: 84.51 )
Ranked among companies with meaningful PS Ratio only.
ACBFF' s PS Ratio Range Over the Past 10 Years
Min: 7.5  Med: 27.5 Max: 295
Current: 84.51
7.5
295
EV-to-EBIT -338.99
ACBFF's EV-to-EBIT is ranked lower than
99% of the 599 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.78 vs. ACBFF: -338.99 )
Ranked among companies with meaningful EV-to-EBIT only.
ACBFF' s EV-to-EBIT Range Over the Past 10 Years
Min: -486.8  Med: 0.1 Max: 585.9
Current: -338.99
-486.8
585.9
EV-to-EBITDA -430.25
ACBFF's EV-to-EBITDA is ranked lower than
99% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.59 vs. ACBFF: -430.25 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACBFF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -711.4  Med: 0.1 Max: 472.6
Current: -430.25
-711.4
472.6
EV-to-Revenue 114.34
ACBFF's EV-to-Revenue is ranked lower than
96% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. ACBFF: 114.34 )
Ranked among companies with meaningful EV-to-Revenue only.
ACBFF' s EV-to-Revenue Range Over the Past 10 Years
Min: -22.4  Med: -0.3 Max: 435.6
Current: 114.34
-22.4
435.6
Current Ratio 7.03
ACBFF's Current Ratio is ranked higher than
53% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. ACBFF: 7.03 )
Ranked among companies with meaningful Current Ratio only.
ACBFF' s Current Ratio Range Over the Past 10 Years
Min: 0.14  Med: 41.19 Max: 1754
Current: 7.03
0.14
1754
Quick Ratio 6.55
ACBFF's Quick Ratio is ranked higher than
64% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.02 vs. ACBFF: 6.55 )
Ranked among companies with meaningful Quick Ratio only.
ACBFF' s Quick Ratio Range Over the Past 10 Years
Min: 0.11  Med: 41.19 Max: 1754
Current: 6.55
0.11
1754
Days Inventory 566.71
ACBFF's Days Inventory is ranked lower than
96% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 116.78 vs. ACBFF: 566.71 )
Ranked among companies with meaningful Days Inventory only.
ACBFF' s Days Inventory Range Over the Past 10 Years
Min: 554.2  Med: 731.76 Max: 909.32
Current: 566.71
554.2
909.32
Days Sales Outstanding 72.44
ACBFF's Days Sales Outstanding is ranked higher than
83% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.10 vs. ACBFF: 72.44 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACBFF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 21.31  Med: 24.25 Max: 72.44
Current: 72.44
21.31
72.44
Days Payable 1.00
ACBFF's Days Payable is ranked lower than
99.99% of the 640 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. ACBFF: 1.00 )
Ranked among companies with meaningful Days Payable only.
ACBFF' s Days Payable Range Over the Past 10 Years
Min: 1  Med: 2397.43 Max: 3988.32
Current: 1
1
3988.32

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -143.00
ACBFF's 3-Year Average Share Buyback Ratio is ranked lower than
97% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. ACBFF: -143.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACBFF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -143  Med: -56.35 Max: -0.3
Current: -143
-143
-0.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 862.00
ACBFF's Price-to-Net-Cash is ranked lower than
56% of the 245 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.33 vs. ACBFF: 862.00 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ACBFF' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.75  Med: 1.17 Max: 930
Current: 862
0.75
930
Price-to-Net-Current-Asset-Value 43.10
ACBFF's Price-to-Net-Current-Asset-Value is ranked lower than
77% of the 490 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.09 vs. ACBFF: 43.10 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ACBFF' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.75  Med: 1.17 Max: 46.5
Current: 43.1
0.75
46.5
Price-to-Tangible-Book 11.01
ACBFF's Price-to-Tangible-Book is ranked lower than
82% of the 774 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. ACBFF: 11.01 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ACBFF' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.35  Med: 1.38 Max: 15.6
Current: 11.01
0.35
15.6
Price-to-Intrinsic-Value-Projected-FCF 5.16
ACBFF's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
89% of the 312 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.58 vs. ACBFF: 5.16 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ACBFF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 2.33  Med: 4.79 Max: 57.5
Current: 5.16
2.33
57.5
Price-to-Median-PS-Value 3.07
ACBFF's Price-to-Median-PS-Value is ranked lower than
96% of the 692 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.08 vs. ACBFF: 3.07 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ACBFF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.36  Med: 1.64 Max: 9
Current: 3.07
0.36
9
Earnings Yield (Greenblatt) % -0.29
ACBFF's Earnings Yield (Greenblatt) % is ranked lower than
67% of the 888 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. ACBFF: -0.29 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACBFF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -136.4  Med: 14.5 Max: 1173.3
Current: -0.29
-136.4
1173.3

More Statistics

Revenue (TTM) (Mil) $32.79
EPS (TTM) $ -0.02
Beta2.01
Volatility158.47%
52-Week Range $1.81 - 12.30
Shares Outstanding (Mil)564.97

Analyst Estimate

Jun18 Jun19 Jun20
Revenue (Mil $) 47 348 681
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.07 0.03 0.14
EPS without NRI ($) -0.07 0.03 0.14
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 22
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}